Brief: CVS Group Says CMA Final Decision Introduces No New Remedies Beyond Provisional Decision
24/03/2026 07:52
March 24 (Reuters) - CVS Group PLC CVSG.L: CVS GROUP PLC - RESPONSE TO CMA SUMMARY FINAL DECISION REPORT CVS GROUP PLC - CMA FINAL DECISION INTRODUCES NO NEW REMEDIES BEYOND PROVISIONAL DECISION CVS GROUP PLC: WELCOMES CMA SUMMARY FINAL DECISION REPORT IN VETERINARY SERVICES MARKET INVESTIGATION CVS GROUP PLC - PRESCRIPTION FEE CAP INCREASED TO £21 INCLUSIVE OF VAT, £12.50 FOR EACH ADDITIONAL DRUG CVS GROUP PLC: BOARD EXPECTS GROUP TO CONTINUE TO TRADE IN LINE WITH MARKET EXPECTATIONS CVS: SOME REMEDIES ARE NOT FULLY JUSTIFIED, BUT WE ARE COMFORTABLE WITH THEM AND BELIEVE THEY ARE WORKABLE Source text: ID:nRSX8560Xa Further company coverage: CVSG.L (((( Reuters.Briefs@thomsonreuters.com ;));))